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PEMBANGUNAN FITOFARMASEUTIKAL  
EURYCOMA LONGIFOLIA JACK DAN PENGAJIAN MEKANISTIK ATAS 
SPERMATOGENESIS TIKUS 
 
 
ABSTRAK 
 
Eurycoma longifolia Jack yang mempunyai kebolehan dalam peningkatan seksual 
and kesuburan lelaki merupakan suatu perubatan tradisional yang terkenal. Berdasarkan 
kepada kajian sebelumnya, ekstrak metanol E. longifolia yang bioaktif difraksinasikan 
melalui kromatografi turus pengisian resin menghasilkani empat fraksi. Di antara keempat-
empat fraksi ini, didapati bahawa fraksi 2 (F2) meningkatkan spermatogenesis tikus dengan 
ketara. Analisis dengan kromatografi cecair prestasi tinggi (HPLC) pada F2 menunjukkan 
bahawa F2 mengandungi sejumlah 32.1 % (w/w) kuassinoid termasuk 14.5 % (w/w) 
eurikomanon. Pemberian F2 secara oral bagi tikus selama 52 hari adalah berkesan untuk 
meningkatkan spermatogenesis. Selain itu, peningkatan kepekatan sperma berikutan dengan 
pemberian F2 terus dibuktikan oleh kajian mikroskopik morfometri di mana populasi sel-sel 
germa, kadar penghasilan spermatozoa, ketinggian epithelium germina dan bilangan sel-sel 
Leydig telah ditingkatkan secara ketara. Kesan E. longifolia ke atas paksi hipotalamus-
pituitari-gonadal juga ditunjuk apabila F2 meningkatkan paras hormon testosteron, hormon 
peluteinan (LH), hormon peransang folikal (FSH) tetapi sebaliknya menurunkan paras 
estrogen dalam plasma. Kajian in vitro membuktikan kesan eurikomanon ke atas sel-sel 
perantaraan testis tikus dalam meningkatkan penghasilan testosteron. Peningkatan paras 
testosteron dan pengurangan estrogen yang diakibatkan oleh eurikomanon secara in vitro 
adalah konsisten dengan kajian in vivo. Eurikomanon menambahkan bilangan cyclic AMP 
dengan merencatkan fosfodiesterase yang kemudiannya meningkatkan steroidogenesis 
testosteron. Eurikomanon juga mengurangkan penghasilan estrogen dengan merencatkan 
enzim aromatase selepas rawatan F2. Tiada apa-apa kesan ketoksikan ditunjukkan daripada 
system pembiakan betina dan perkembangan fetus-fetus. Paras ketidakjumpaan kesan buruk 
 xxviii
 xxix
(NOAEL) untuk toksikologi pembiakan dan teratologi tikus adalah 100 mg/kg. Di samping 
itu, kesan pengumpulan bahan kimia oleh fetus mungkin tidak menjadi disebabkan 
bioperolehan kuassinoid yang agak rendah disebabkan polariti yang tinggi, keterlarutan lipid 
yang lemah, separuh hayat yang pendek dan kadar pelupusan yang tinggi. Di samping 
peningkatan androgen selepas pengambilan F2 melalui mulut, tiada kesan toksik pada gonad 
jantan dijumpai. Lebih-lebih lagi, F2 tidak menunjukkan kesan apoptosis pada sel-sel germa 
berbanding dengan kawalan. Oleh itu, F2 atau fraksi E. longifolia yang kaya dengan 
kuasinoid mungkin bernilai untuk dibangunkan sebagai suatu fitofarmaseutikal bagi 
menangani ketidaksuburan lelaki.                      
 
   
 
 
THE PHYTOPHARMACEUTICAL DEVELOPMENT OF  
EURYCOMA LONGIFOLIA JACK AND ITS MECHANISTIC STUDIES ON 
RAT SPERMATOGENESIS 
 
 
ABSTRACT 
 
Eurycoma longifolia Jack is popularly used as a traditional medicine for various 
pharmacological properties including the improvement of sexual and male fertility. From a 
previous study, the bioactive methanol extract of E. longifolia was fractionated through 
resin-packed column chromatography and yielded four fractions. The fraction 2 (F2) 
significantly increased the spermatogenesis of rats. High performance liquid chromatography 
(HPLC) analysis revealed that the bioactive fraction F2 contained 32.1 % (w/w) of total 
major quassinoids comprising 14.5 % (w/w) of eurycomanone. The male rats orally 
administered with 25 mg/kg of F2 and 250 mg/kg of E. longifolia aqueous extract that 
contained almost similar in concentration of eurycomanone, significantly increased the 
sperm concentration when compared with that of the control animals. Upon oral 
administration of F2 for 52 days, male rats showed an improvement of the spermatogenesis. 
The increase of the sperm concentration upon treatment with F2 was further confirmed by 
the microscopic morphometrical studies showing that the population of the germ cells, 
spermatozoa production rate, the height of germinal epithelium and Leydig cells count was 
significantly elevated. The administration of F2 increased the levels of testosterone, 
luteinizing hormone, follicle stimulating hormone but reduced the estrogen level in plasma, 
further indicates the effect of E. longifolia on the hypothalamic-pituitary-gonadal axis. In 
vitro study showed that eurycomanone, the major quassinoid, significantly increased the 
testosterone production in the isolated rat testis interstitial cells. The increase in testosterone 
and decrease in estrogen induced by eurycomanone in vitro were consistent with the in vivo 
study. Eurycomanone inhibited phosphodiesterase resulting in the accumulation of cyclic 
AMP that subsequently modulated the steroidogenesis of testosterone, and also reduced 
 xxx
 xxxi
estrogen production by inhibiting the aromatase enzyme. Upon oral treatment of female rats, 
F2 was not toxic to the female reproductive system and the development of foetuses. The no-
observed adverse effect level (NOAEL) for reproductive toxicology and teratology was 100 
mg/kg in rats. The possible cumulative chemicals exposure of foetus probably may not arise 
as the bioavailability of the bioactive quassinoids was relatively low due primarily to the 
high polarity, poor lipid solubility, short half life and high elimination rate. Male rats orally 
administered with F2 did not show toxic effects on the gonads despite the androgen elevation 
property of the fraction. Furthermore, F2 showed no apoptotic effect on the germ cells when 
compared to control. Hence, E. longifolia quassinoid-rich fraction F2 may be worthy for the 
development as a phytopharmaceutical for alleviating the infertile male. 
 
 
   
 
 
CHAPTER ONE 
INTRODUCTION 
 
1.1 Infertility: An Overview  
Infertility is generally defined as the inability of a couple to conceive after trying 
through unprotected intercourse for a year (Prakash, 2007). In all cultures worldwide, 
infertility is recognized as a crisis that has a potential to agitate the stability of individuals, 
relationships among the family members as well as the community welfare (Burns and 
Covington, 2006). Globally, one in ten couple experienced infertility (Burns and Covington, 
2006). According to World Health Organization (WHO), over 186 million couples in 
developing countries (except China) were affected by infertility (WHO, 2003). Among the 
infertile couples, about 20 % of the infertility problem originated from the male partner and 
30-40 % was contributed by both male and female (Raman et al., 2005). Among infertile 
males, over 90 % were diagnosed as oligozoospermia, a clinical condition known as low or 
poor in sperm quality (Winston, 1986) with a population of < 15 × 106 spermatozoa/mL 
compared to the normal of > 15 × 106 spermatozoa/mL (WHO, 2010). Moreover, former 
meta-analyses data of the sperm count showed a global downward trend (Merzenich et al., 
2010). 
 
1.1.1   Oligozoospermic male infertility 
Hitherto, the origin of the oligozoospermic male infertility is unclear and yet it was 
believed that the defect may be caused primarily by one or a combination of several factors 
including personal lifestyle (frequent uses of electronic devices, wearing tight attire, horse 
riding, etc.), diet, working habits (long hours of driving, stress, strenuous work), etc. (Sharpe 
and Franks, 2002). Besides, physiological changes such as immunological abnormalities, 
erectile dysfunction, anatomical abnormality and genetic disorders may also contribute to the 
male infertility (Winston, 1986).  
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1.1.2   Challenges of the treatment approach on male infertility  
For decades, the investigation of female reproductive functions has stood in the 
foreground however the studies on male fertility have only been given an equal attention in 
the recent years (Nieschlag, 2010). Earlier study reported that glutathione, an antioxidant, 
protected the epididymis, spermatogenic epithelium and ejaculated spermatozoa from 
excessive generation of reactive oxygen species (Irvine, 1996). However, fertility studies on 
glutathione for male infertility treatment still remain obscured. Acupuncture improved the 
ultrastructure of spermatozoa for idiopathic male infertility but not to the number of 
spermatozoa (Pei et al., 2005). Medical treatments including human chorionic gonadotropin 
(hCG), antiestrogen, recombinant follicle stimulating hormone (rFSH), surgery and 
microsurgery involving the sperm intra-fallopian transfer and intra-cytoplasmic sperm 
injection (ICSI) have been developed to overcome the male infertility but not to enhance the 
sperm quality (Jungwirth et al., 2012). In fact, these treatments are not only costly but have 
also led to socio-economic problems (Katz et al., 2002). Besides, a potent aromatase 
inhibitor was developed to improve the reproductive activity and spermatogenic function of 
animals however, the route of administration that used surgically implanted osmotic pump 
was not appropriate as a treatment method (Kawakami et al., 2004). In addition, direct 
exogenous oral administration of testosterone did not improve the spermatogenesis on the 
idiopathic male infertility (Sheckter et al., 1989) but may in turn cause liver toxicity (Ishak 
and Zimmerman, 1987). Therefore, alternatives to overcome infertility that are more 
affordable and easily available such as traditional herbal treatment, are gaining in popularity 
today for the treatment of oligozoospermia. 
 
1.1.3   Introduction to natural products 
Natural products from herbs are recognized as one of the fastest growing industry all 
over the world. In fact, this industry has long been in practice as from pre-historic epic along 
with the growth of human civilization. In the ancient time, medicinal treatment was based on 
herbal as a practice and most of these practices in the herbal treatments indeed are being 
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vertically and verbally passed down from one generation to the next. As the ingredient of the 
herb was not very well studied, the practice was eventually challenged by synthetic drugs, 
produced following the development of the chemistry during 14 and 15 century in the West. 
To date, thousands of the herbal natural products that are manufactured in the form of 
capsule, soft-gel, powder in sachet and even in the canned beverages are available as over-
the-counter supplements. Herbal natural products may possess various biological properties 
such as antineoplastic, antibacterial, antiviral, antipyretic, antidiabetic, antioxidant, 
antifertility, etc., but the safety and efficacy of the herbal natural products are still not fully 
studied.  
 
1.2    Traditional herbal medicine on male infertility 
Plant-based chemical ingredients have been resourceful as new therapeutic agents 
following the continuously broad research and development during the last century (Mérillon 
and Ramawat, 1999). Protodioscin, a phytochemical agent derived from Tribulus terrestris L. 
plant has been clinically proven to improve sexual desire and erectile dysfunction 
(Gauthaman et al., 2002). However, geographical factors caused the inconsistency on the 
production of protodioscin (Adimoelja, 2000). Ferulic acid, as an effective constituent 
commonly found in various medicinal herbs increased sperm viability and motility in 
asthenozoospermic infertile human spermatozoa in vitro (Zheng and Zhang, 1997), however 
no in vivo study was available. Besides, pychnogenol (French maritime tree bark extract), L-
carnitine, minerals such as zinc, selenium and supplements including vitamin B12, C, E and 
coenzyme Q10 showed improvement in male fertility (Gutmann and Covington, 2006). 
Flavonoids from plants that increased the catalase and superoxide dismutase (SOD) activities 
but decreased the lipid peroxidation level was believed for the semen quality improvement of 
oligozoospermic infertile men (Lara et al., 2008). In addition, some plants such as Spilanthes 
acmella (Sharma et al., 2011), Bryonia laciniosa (Chauhan and Dixit, 2010), Anacyclus 
pyrethrum DC (Sharma et al., 2013), Lepidium meyenii (Zheng et al., 2000), Hibiscus 
macranthus and Basella alba (Moundipa et al., 1999) showed androgenic, aphrodisiac and 
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spermatogenic activities. In Malaysia, traditional medicinal plants reported to increase male 
virility included Coleus parviflorus (Ubi Kemili), Smilax myositiflora (Ubi Jaga), Polyalthia 
bullata (Tongkat Ali Hitam) and Eurycoma longifolia (Zakaria and Ali Mohd., 1994). 
Amongst, E. longifolia is popularly used as a traditional ethno-remedy for the improvement 
of male libido, sexual prowess and fertility (Gimlette, 1971; Ang and Sim, 1998; Noor et al., 
2004; Chan et al., 2009; Zanoli, et al., 2009; Wahab et al., 2010). Most of the traditional E. 
longifolia remedies are prepared by boiling the powdered roots with water, and the dry 
powdered extract is presently incorporated into over 200 canned beverages of carbonated 
drink, instant premixed tea and coffee for sale in the domestic market (Cyranoski, 2005).   
 
 
1.3 Literature review 
1.3.1   Eurycoma longifolia Jack: a traditional approach towards male infertility 
 
Malaysia is a tropical country enriched with millions of flora and fauna and this 
biodiversity has contributed a reservoir of herbal sources yet to be discovered. The climate 
with high humidity and rainfall in Southeast Asia provides the best ecosystem for the growth 
of plants. Amongst, Eurycoma longifolia Jack, a small tree belonging to Simaroubaceae 
family, locally known as ‘Pasak bumi’ in Indonesia, ‘Cay ba binh’ in Vietnam and ‘Tongkat 
Ali’ in Malaysia (Gimlette, 1971). The plant thrives very well in the tropical climatic 
conditions, commonly found along the hilly jungle slopes and widely distributed in the 
primary, secondary, evergreen and mixed deciduous forests in Malaysia, Indochina, Sumatra, 
Borneo and the Philippines (Kuo et al., 2003). 
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Plate 1.1 Eurycoma longifolia Jack 
 
 
 
1.3.1(a)  Monograph and physiology of Eurycoma longifolia Jack 
E. longifolia is a medium size slender shrub or tree reaching up to 10 m in height. 
The plant is often unbranched with reddish brown petioles (Malaysian Monograph 
Committee, 1999) or with a few upright branches and each of them is crowned by an 
umbrella-like rosette of leaves (Corner, 1951). The leaves of the plant reach a length of about 
1 m, even pinnate, consist of 30-40 leaflets and dark green in colour. Each leaflet is about 5-
20 cm long, 1.5-6.0 cm wide and much paler on the ventral side (Malaysian Monograph 
Committee, 1999). The flowers are wide, about 0.5 cm, hairy and purplish-crimson in colour 
(Corner, 1951). The petals of the flowers are small and have very fine pubescent (Malaysian 
Monograph Committee, 1999). The male and bisexual (hermaphrodite) flowers appear on the 
different trees and are slightly fetid (Corner, 1951). The fruits are about 1.0-1.5 cm in length, 
hard, ovoid in shape, yellowish brown in colour when young and will turn brownish red 
when ripe (Malaysian Monograph Committee, 1999). 
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1.3.1(b)  Taxonomy of E. longifolia (Hsuan, 1978) 
Kingdom:  Plantae 
Division:  Spermatophyta 
Subdivision:  Angiospermae 
Class:  Dicotyledoneae 
Order:  Geraniales 
Family:  Simaroubaceae 
Genus:  Eurycoma 
Species:  longifolia Jack 
 
 
1.3.1(c)   Chemical constituents of E. longifolia  
For 30 years since the first scientific documentation on E. longifolia in 1982, more 
than 60 chemical constituents have been isolated and characterized.  E. longifolia contains 
different types of chemical constituents which can be generally classified into six major 
groups including quassinoids, alkaloids, anthraquinones and their glucosides, tirucallane-
type triterpene, squalenes and biphenylneolignans. Table 1.1 showed the list of chemical 
constituents discovered from the plant following the year of its documentation.  
 
Table 1.1 List of novel chemical constituents isolated from E. longifolia. 
Name of chemical constituents References 
Laurycolactone A, laurycolactone B, eurycomalactone Suong et al. (1982) 
Eurycomanone (1), eurycomanol (2) Darise et al. (1983) 
3,4-Dehydroeurycomalactone, 5,6-dehydroeurycomalactone, 6-
hydroxy-5,6-dehydroeurycomalactone 
Bates et al. (1984) 
10-Hydroxycanthin-6-one Chan et al. (1986) 
Eurycomanol-2-O-β-D-glycopyranoside Chan et al. (1989) 
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 Table 1.1 Continued. 
Name of chemical constituents References 
Longilactone, 13,21-dihydroeurycomanone (3) , 13β,21-
dihydroxyeurycomanone, 14,15β-dihydroxyklaineanone   
Morita et al. (1990) 
13β,18-Dihydroxyeurycomanol Chan et al. (1991) 
Eurylene, teurilene Itokawa et al. (1991a) 
Longilene peroxide Itokawa et al. (1991b) 
Biphenylneolignans Morita et al. (1992) 
6α-Hydroxyeurycomalactone Chan et al. (1992) 
11-Dehydroklaineanone, niloticin, dihydroniloticin, piscidinol A, 
bourjotinolone A, 3-episapelin A, melianone, hispidone  
Itokawa et al. (1992)  
Eurylactone A, eurylactone B Itokawa et al. (1993) 
14-Deacetyl eurylene Morita et al. (1993a) 
6-Dehydroxylongilactone, 7α-Hydroxyeurycomalactone, 13α(21)-
epoxyeurycomanone (4), 15-acetyl-13α(21)-epoxyeurycomanone, 
12,15-diacetyl-13α(21)-epoxyeurycomanone, 12-acetyl-13,21-
dihydroeurycomanone, 15β-acetyl-14-hydroxyklaineanone, 6α-
acetoxy-14,15β-dihydroxyklaineanone, 6α-acetoxy-15β- 
hydroxyklaineanone     
 
Morita et al. (1993b) 
9,10-Dimethoxycanthin-6-one, 10-hydroxy-9-methoxycantin-6-one, 
11-hydroxy-10-methoxycantin-6-one, 5,9-dimethoxycanthin-6-one, 
9-methoxy-3-methylcanthin-5,6-dione, canthin-6-one, canthin-6-one-
3N-oxide, 9-methoxycanthin-6-one, 1-methoxymethyl-β-carboline, 
β-carboline-1-propionic acid, 11-hydroxycanthin-6-one, 9-
methoxycanthin-6-one-3N-oxide, 3-methylcanthin-5,6-dione  
 
Mitsunaga et al. (1994) 
Eurycolactone A, Eurycolactone B, Eurycolactone C 
  
Ang et al. (2000) 
9-Hydroxycanthin-6-one, 9-hydroxycanthin-6-one-N-oxide, 
chrysophanol, parietin, emodin, emodin-8-O-β-glucoside, 
aloeemodin-8-O-β-glucoside, pulmatin, chrysophanein, parietin-8-O-
β-glucoside  
   
Lin et al. (2001) 
Eurycolactone D, Eurycolactone E, Eurycolactone F 
 
Ang et al. (2002) 
12-Epi-11-dehydroklaineanone, 15β-hydroxyklaineanone 
 
Jiwajinda et al. (2002) 
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Table 1.1 Continued. 
 
Name of chemical constituents References 
n-Pentyl β-carboline-1-propionic acid, 5-hydroxymethyl-9-
methoxycantin-6-one, 1-hydroxy-9-methoxycantin-6-one, methyl β-
carboline-1-carboxylate, 4,5-dimethoxycantin-6-one, 10-
methoxycantin-6-one, 8-hydroxy-9-methoxycantin-6-one, 5-
methoxycantin-6-one, 5-hydroxymethylcantin-6-one, picrasidine Q, 
7-methoxymethyl-β-carboline-1-propionic acid, canthin-6-one 9-O-
β-glucopyranoside, 1-hydroxycanthin-6-one 
 
Kuo et al. (2003) 
Eurycomaoside 
 
Bedir et al. (2003) 
Eurycomalide A, eurycomalide B, 13β,21-dihydroxyeurycomanol, 
5α, 14β,15β-trihydroxyklaineanone   
 
Kuo et al. (2004) 
14-Epi-13,21-dihydroeurycomanone, 12,15-O,O-diacetyl-13,21-
dihydroeurycomanone, 6α, 14β,15β-trihydroxyklaineanone, 
ailanquassin A, 3α,4α-epoxyeurycomalide B, 3ξ,4ξ-epoxy-5,6-
dehydroeurycomalactone, 5α-hydroxyeurycomalactone, 5-dehydro-3-
hydro-7β-hydroxy-6-oxoeurycolactone E, ∆4(18)-eurycolactone E 
isomer, 6α-hydroxyeurycolactone E  
 
Miyake at al. (2009) 
2,3-Dehydro-4α-hydroxylongilactone, scopolin 
 
Teh et al. (2010) 
 
  
 
1.3.1(d)   Pharmacological aspect of E. longifolia  
E. longifolia is popularly sought after as herbal remedies to treat various diseases. 
The root of the plant, in particular, has long been used for the treatment of fever, headache, 
intestinal worms, ulcers, pain (Perry and Metzger, 1980) and consumed as sexual tonic 
(Gimlette, 1971).       
 
Scientific interest in E. longifolia took impetus late in the 20th century following 
observation of its potent activity against malaria and cytotoxicity on cancer cell lines. Chan 
et al. (1986; 2004) reported that the quassinoids, eurycomanone (1) possessed anti-
plasmodial effect against the multi-drug resistant Thailand K1, chloroquine-resistant 
Gombak A and chloroquine-sensitive D10 strain of Plasmodium falciparum parasite. 
Moreover, 1 was also found to be cytotoxic against human breast cancer cell lines MCF-7 
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(Kuo et al., 2004) and P388 leukaemia cells (Morita et al., 1990). Besides, a eurycomanone-
enriched fraction was also reported to induce apoptosis via the p53 pathway in HepG2 liver 
cancer cells (Zakaria et al. 2009). Eurycomanone (1) was also reported to suppress the 
protein expression of prohibitin, annexin I and endoplasmic reticulum protein 28 that involve 
in the cell cycle regulation in A-549 lung cancer cells (Wong et al., 2012). Apoptosis 
activation via caspase 9-independent pathway has been reported for one of the crude 
fractions of E. longifolia in MCF-7 breast cancer cells (Tee et al. 2007). However the 
bioactive chemical constituents in the fraction were not clearly defined. In addition, one of 
the alkaloids 9-methoxycanthine-6-one, isolated from the root of E. longifolia showed 
cytotoxic effects against A-549 and MCF-7 cell lines (Kuo et al., 2004). Beside antimalarial 
and cytotoxic properties, 1 also possessed antipyretic properties (Chan et al., 1995). 
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Figure 1.1. Chemical structure of the four major quassinoids: eurycomanone (1), 
eurycomanol (2), 13,21-dihydroeurycomanone (3) and 13α(21)-epoxyeurycomanone (4).   
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Beginning from the late 1990, huge attention has been focused on the aphrodisiac 
properties of E. longifolia (Ang and Sim, 1997). Since then, more than twenty scientific 
reports and proceedings on the E. longifolia aphrodisiac enhancement in experimental 
animals have been published and presented (Bhat and Karim, 2010), however there are no 
clinical evidence to support the animal findings. Furthermore, possible mechanistic actions 
of the bioactive chemical constituents that repeatedly showed the aphrodisiac activity have 
not been clearly elucidated. A recent study demonstrated that E. longifolia had no significant 
enhancement effect on the sexual performance of the sluggish rodents but concluded that the 
improvement of the sexual performance could be primarily attributed to the elevation of 
serum testosterone level (Zanoli et al., 2009).         
 
Renewed interest in E. longifolia on the fertility improvement effect began in 2001 
when Lin et al. (2001) reported that the ethanolic extract of E. longifolia concomitant with 
the human chorionic gonadotropin (hCG) increased the testosterone production of the Leydig 
cells. Therefore, the involvement of the hCG and the testosterone following the E. longifolia 
treatment may hypothesize that the plant may improve the male fertility. Three years later, 
Noor et al. (2004) showed that aqueous extract of E. longifolia increased the sexual 
behaviour and sperm quality of the experimental animals. However, the bioactive chemical 
constituents and the possible mechanism of actions were still not clearly defined. According 
to Noor at al. (2004), the aqueous extract significantly increased the male sexual behavior 
and increased the sperm quality, reversed the adverse effect of estrogen in male rats (Wahab 
et al., 2010), improved the sperm quality of idiopathic infertility clinically (Tambi and Imran, 
2010), enhanced sexual well-being (Ismail et al., 2012) and increased the testosterone level 
of the late-onset hypogonadism males (Tambi et al., 2011). In fact, Asiah et al. (2007) 
proposed that a glycopeptide of 4.3 kDa, known as eurypeptide in the E. longifolia aqueous 
extract was the aphrodisiac marker. However, the glycopeptide was not indigenously found 
in E. longifolia, but also detected in Smilax myosotiflora, Rafflesia sp. and Labisia pumila 
(Asiah et al., 2007). Hitherto, the absolute structural configuration was not documented 
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(Asiah, et al., 2007). Beside the glycoproteins, the aqueous extract also contained the low 
concentration of the quassinoids especially 1 as reported by Tambi et al. (2011) and Shuid et 
al. (2011). In contrast, the crude polar organic extract of E. longifolia containing greater than 
2 % of quassinoids including 1, improved the sperm concentration of the normal and 
oligospermic animals (Chan et al., 2009). Thus, 1 and the quassinoids which co-exist in both 
aqueous and organic polar extracts may play an important role in the male reproductive 
system. Beside the male, 1 was also involved in the improvement of the female reproductive 
disorder (Abdulghani et al., 2012).     
 
In view of the quassinoid 1 showing potential improvement of spermatogenesis, a 
bioactivity-guided fractionation of E. longifolia was performed to selectively yield an extract 
that contained high concentrations (> 10 % w/w) of 1 and its analogues, eurycomanol (2), 
13,21-dihydroeurycomanone (3) and 13α(21)-epoxyeurycomanone (4) (Low et al., 2011; 
Chan et al., 2012). Therefore, the detailed pharmacological properties of the quassinoid-rich 
E. longifolia extract including its efficacy on the spermatogenesis cycle, sperm production 
rate and male fertility improvement effects were investigated.      
 
 
1.3.1(e)   Bioavailability and pharmacokinetics studies of E. longifolia  
 
Bioavailability is a measure of the degree in which a dose of a substance becomes 
physiologically available to the body tissue. A pharmacokinetic profile relates to the 
measurement or modeling of the absorption, distribution, metabolism and excretion of drugs 
or chemicals in a biological system as a function of time (Abou-Donia, 1995). The 
pharmacokinetic profile of a drug or chemical substances is clinically important as its 
pharmacological and toxicity effects virtually depends on the dosage and bioavailability. By 
knowing the absolute bioavailability, various factors that affect the absorption of the 
chemicals or drugs can then be further investigated to optimize the disposition in the 
systemic circulation (Tan, 2004). 
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Following the administration of a chemical or drug in an oral dosage form, 
disintegration and dissolution of the compound should occur rapidly to ensure satisfactory 
absorption. The physico-chemical properties such as lipophilicity and pH stability of the 
compounds have been considered as the major factors prior to absorption of the compounds 
as such cellular membrane of the epithelium cells lining up on the surface of intestinal tract, 
facilitating the absorption of any chemical constituent, can be considered as a combination of 
a physico-chemical and biological barrier to drug transport (Van de Waterbeemd, 2003). 
Beside the physico-chemical aspects of the substances, pre-systemic metabolism also known 
as high first pass effect may also influence the bioavailability of a drug or chemical 
substances during absorption when given orally (Tan, 2004). 
  
Plant-based chemical substances often face the common dilemma of low absorption 
or poor oral bioavailability. Flavonoids from the Gingko biloba extract (Pietta et al., 1995), 
magnesium lithospermate B (MLB) isolated from Salvia miltiorrhiza (Zhang et al., 2004b), 
ginsenosides from Panax notoginseng (Xu et al., 2003), quaternary ammonium 
protoberberine from Corydalis saxicola (Li et al., 2006), lignans from Phyllanthus niruri 
(Murugaiyah and Chan, 2007) and curcumin from Curcuma longa (Yang et al., 2007) were 
reported to be poor in oral bioavailability. In addition, Tan et al. (2002) reported poor 
absorption of 9-methoxycanthine-6-one, an alkaloid isolated from the root of E. longifolia 
when administered orally to rats. Previous study reported that 1, possessing poor 
lipophilicity with low log Kow value, was poorly bioavailable in the circulation due mainly to 
the high polarity of the compound (Low et al., 2005). However, the bioavailability of the 
other major quassinoids, 2, 3 and 4 in the quassinoid-rich E. longifolia extract remain 
obscure. Thus, the pharmacokinetic parameters of 2, 3 and 4 were investigated and compared 
with 1 following oral and intravenous administration in rats. The physico-chemical 
properties of lipophilicity and pH stability of the quassinoids influencing their absorption in 
the gastro-intestinal tract were studied. 
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 1.3.1(f)   Toxicology aspect of E. longifolia 
Toxicology is defined as a study of the adverse effects of chemicals or other agents 
on the living systems in order to predict the potential harmful effects to man and the 
environment (Conning, 1993). According to the Food and Drug Authority’s regulations in 
Good Laboratory Practices, toxicology and pharmacokinetic properties of a drug must be 
evaluated and documented in animals prior to human study (The Merck Manual of Diagnosis 
and Therapy, 2005). The safety of the drug is determined by studying the acute, subchronic 
and chronic exposure of the drug in several animal species through various route of 
administration (The Merck Manual of Diagnosis and Therapy, 2005). Furthermore, any 
chemical substance that would be used on fertility improvement were required to be 
investigated for its possible toxic effect on the reproductive system and teratological defects 
using the animal model (OECD 421, 1995; OECD 416, 2001).  
 
Formerly, acute toxicity test methods were designed to provide the dose-response 
curve by using several animals at each of three to five test doses of chemicals or drugs. By 
following this conventional method, the tolerance of the test population of laboratory 
animals towards potentially lethal doses was measured (Rispin et al., 2002). According to 
Rispin et al. (2002), the introduction of the new up-and-down procedure (UDP) on the 
median lethal dose (LD50) was highly recommended and accepted. The efficiency of the new 
UDP dosing allowed the LD50 to be estimated using relatively fewer animals compared to 
that of the conventional acute toxicity test fixed-dose protocol (OECD 420, 2001). In 
addition, the present study also investigated the possible toxic effect of the bioactive E. 
longifolia quassinoid-rich fraction on the female reproductive system and prenatal 
development of the foetuses after oral administration of the extract. In fact, this information 
is essential for assessing risk-to-benefit ratio of the product, providing a reference to initiate 
clinical studies and to assess the potential toxicity.  
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A previous study reported that the LD50 of the 34 % alcoholic extract of E. longifolia 
was 1500-2000 mg/kg in mice (Satayavivad et al., 1998). However, the chemical profile of 
the extract was not clearly described. Nevertheless, one study showed that the LD50 of the 1 
on the mice and brine shrimp was reported to be 50 mg/kg and 3.5 µg/mL, respectively 
(Chan and Choo, 2002). However, the toxicity signs, symptoms and necropsy of the dead 
animals were not reported. Recently, Shuib et al. (2011) reported that E. longifolia water 
extract should be used with caution especially in the elderly or patients with liver problems. 
In contrast, preliminarily sub-chronic 90-day toxicity study with a quassinoid-rich E. 
longifolia extract, no treatment-related adverse effects, significant changes of body weight, 
organ weight, haematology, serum biochemistry, food and water consumption of the treated 
animals were observed when compared to the control (Low, 2005). Furthermore, following 
the 180-day chronic oral administration of the same extract, the animals showed some 
changes in the blood haematological profiles regardless of genders (Low, 2005; Low et al., 
2013). Changes on serum biochemical parameters were sporadically observed in both 
genders of the treatment groups but were without a dose-dependence relationship. Hence, a 
dosage of 50 mg/kg quassinoid-rich E. longifolia extract upon 90 and 180 days oral 
administration on rats was relatively safe (Low, 2005). 
 
1.3.2   Male reproductive system  
 Organs in the male reproductive system comprise testes, a system of ducts, accessory 
sex glands such as prostate and several supporting structures including the scrotum and penis 
(Prakash, 2007) (Plate 1.2). Testes, located externally in the scrotum, are the male gonads that 
produce sperm and secrete hormones. The male reproductive system consists of the 
seminiferous tubules in testes, the vasa efferentia, the epididymis, the vas deferens and the 
urethra (Guyton and Hall, 1996). This system of ducts concerns with the production and 
maturation of spermatozoa in testes, storage of spermatozoa in epididymis and finally 
transporting the spermatozoa to the exterior during ejaculation. The accessory sex organs 
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including seminal vesicles and prostate glands produce the seminal fluid containing protein 
and vitamin to nourish the spermatozoa and their motility.     
 
 
 
 
 
 
 
 
 
 
 
Plate 1.2. Human male reproductive system. Depicted from Prakash, (2007). 
 
 
 
 
 
 
 
 
 
 
 
Plate 1.3. Arrangement of the germ cells or spermatocytes, Sertoli cells and interstitial or 
Leydig cells in seminiferous tubules. Depicted from Prakash (2007). 
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 Testes are paired oval glands located externally in the scrotal sac. Testes contain 
sperm producing coiled tubules known as seminiferous tubules. Seminiferous tubules are 
long, convoluted and lined by highly specialized epithelium called spermatogenic cells and 
supporting cells known as Sertoli cells (Setchell, 1978). Spermatogenic cells including 
spermatogonia (stem), spermatocytes (germinal) and spermatids (undifferentiated 
spermatozoa) are the elements of germ cells development in the process known as 
spermatogenesis (Clermont, 1972) (Plate 1.3). Sertoli cells or also known as sustentacular 
cells form blood-testis barrier, provide support and nutrition to the developing spermatogenic 
cells, phagocytize the defected spermatocytes and synthesize androgen binding protein (ABP) 
and inhibin (Guyton and Hall, 1996). Sertoli cells are stimulated by follicle stimulating 
hormone (FSH) to produce androgen binding protein (ABP) and inhibin. ABP binds to 
testosterone secreted by the Leydig cells to facilitate the spermatogenesis process. On the 
other hand, inhibin in turn back regulates the secretion of FSH on pituitary gland. The 
intertubular or interstitial connective tissues are filled with blood vessels, macrophages, 
lymphocytes and a group of cells known as interstitial cells or interstitial endocrinocytes or 
Leydig cells (Setchell, 1978). Leydig cells are responsible for the production of androgen or 
male sex hormone testosterone following a process called steroidogenesis which is regulated 
by the luteinizing hormone (LH) secreted from pituitary gland. Hence, the spermatogenesis 
and steroidogenesis are intimately regulated by series of hormones that form an 
endocrinological regulatory system (Prakash, 2007).                
 
1.3.2(a)   Endocrinology regulation of male reproductive system    
 The endocrine system comprises a number of glands that release a product known as 
hormone into the adjacent tissues or into body fluids (Prakash, 2007). Hormone is defined as 
a chemical substance secreted by the glands of endocrine system into blood circulation 
system and carried to the target cells throughout the body. Hormones have powerful 
biological effect even at very low concentration. Chemically, hormones can be classified in 
the two major classes known as lipid soluble hormones such as steroid (testosterone and 
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estrogen) and thyroid hormones, distinguished from the water soluble hormones including 
peptides (insulin) and glycoprotein (FSH and LH).   
 
 
Figure 1.2. Hormonal regulation of testicular function by hypothalamus and pituitary known 
as hypothalamus-pituitary-gonadal axis. Modified from the figure depicted from Prakash 
(2007). 
 
 
1.3.2(b)   Hypothalamic-pituitary-gonadal axis  
In general, the release of the gonadotropins, LH and FSH into the general circulation 
is stimulated by the GnRH from the hypothalamus. This allowed the depiction of a system 
known as hypothalamic-pituitary-gonadal (HPG) axis whereby the secretion of the 
gonadotropins modulates the secretion of androgens in the gonad and yet the elevated 
androgen level will inhibit back the secretion of the GnRH and gonadotropins (Prakash, 
2007) (Fig. 1.2). In addition to inhibin, the major inhibitory effect of androgen on the 
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hypothalamus on gonadotropin release or known as negative feedback is mediated 
principally by estrogen and derives locally from the testosterone aromatization mainly in the 
germ cells and Sertoli cells (Carreau et al., 2011).  
 
However, a recent study showed that GnRH releasing cells did not possess any sex 
steroid receptors including estrogen receptors but contained the kisspeptin receptor GPR54 
and most of the kisspeptin producing cells possessed alpha estrogen receptor (α-ER) (Clarke, 
2011). Therefore, estrogen may indirectly modulate the GnRH producing neurons by 
stimulating kisspeptin producing cells to secrete kisspeptin. The kisspeptin will in turn 
attenuate the GnRH production by acting on GnRH cells in hypothalamus (Clarke, 2011). 
Beside kisspeptin, a novel gonadotropin inhibitory hormone (GnIH) may also regulate the 
secretion of gonadotropins by modulating the GnRH cells (Clarke, 2011).    
 
Development and maintenance of male reproductive system and secondary sex 
characteristics in males is mediated by testosterone (Prakash, 2007). The production of 
testosterone by Leydig cells in testes is influenced by LH or formerly known as interstitial 
cell stimulating hormone (ICSH) of the anterior pituitary. The secretion of LH in turn is 
regulated by gonadotropin-releasing hormone (GnRH), a decapeptide produced by 
hypothalamus. In fact, GnRH not only stimulates the release of LH, but also FSH in the 
anterior pituitary. By acting on the Sertoli cells in seminiferous tubules, FSH is mainly 
responsible for the initiation of spermatogenesis whilst full maturation of the spermatozoa 
from spermatids required both FSH and testosterone (Ruwanpura et al., 2010).  
 
1.3.2(c)   Spermatogenesis 
Spermatogenesis is a process that produces the male gametes known as spermatozoa 
(Odell and Moyer, 1971). The process occurs in the coiled seminiferous tubules of the testis 
where the gonocytes produce germ cells that subsequently transform into the premature 
spermatozoa called spermatids (Prakash, 2007). Seminiferous epithelium is composed of 
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non-proliferating population of supporting cells known as Sertoli cells and a proliferating 
population of germ cells comprising spermatogonia, spermatocytes and spermatids (Setchell, 
1978). The duration of cycle for the development from spermatogonia to mature spermatid is 
about 12.9 days and about 45-50 days to complete a spermatogenesis in rats (Clermont, 1972; 
Hisatomi et al., 1996).  
 
Spermatogenesis can be divided into three distinct phases. The first phase is the 
mitotic multiplication and the growth of spermatogonia, which proliferates to spermatocytes 
and simultaneously maintains their number by renewal. In rat, spermatogonia undergo six 
mitotic divisions that subsequently become preleptotene spermatocytes. The second phase is 
the reduction phase involving primary and secondary spermatocytes, which have gone 
through the process of the meiotic division, produces genotypic haploid cells known as 
spermatids (Clermont, 1972). In the second phase, the spermatocytes in the meiotic division 
develop through leptotene, zygotene and pachytene to become secondary spermatocytes 
(Maeda et al., 2000). The third phase involves the spermiogenesis of spermatids, which leads 
towards the differentiation and transformation of spermatids into a spermatozoon (Odell and 
Moyer, 1971; Clermont, 1972). Over the past four decades, major researches using 
innovative technologies such as immunocytochemistry, proteomic, genomic and genetically 
modified animal models have refined the roles of FSH and testosterone in the 
spermatogenesis. Earlier studies showed that FSH regulated the spermatogonial development 
whilst testosterone solely facilitated spermiogenesis (Ruwanpura et al., 2010).     
 
In general, germ cell development involves the series of mitotic and meiotic 
divisions and it has been generally accepted that a stable population of germ cells is 
determined by the balance between the active division and death (apoptosis) of the cells 
(Ruwanpura et al., 2010). These processes are highly influenced by the FSH and testosterone 
at the Sertoli cells that regulate the survival of the germ cells as the germ cells do not contain 
hormone receptors (Ruwanpura et al., 2010). In fact, the biological effects of the germ cells 
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such as spermatogenesis are exerted through the receptors localize in/on the Sertoli cells that 
require junctional and functional communications between the germ and the Sertoli cells 
(Ruwanpura et al., 2010). Recent study has revealed that estrogen, which is derived from the 
irreversible aromatization of the testosterone in the Leydig cells, was controlling the 
apoptosis, maturation and differentiation of the haploid germ cells (Carreau et al., 2011). 
Hence, undoubtedly, testosterone is essential for spermatogenesis. The biosynthesis process 
of testosterone, commonly known as steroidogenesis, is virtually not associated with the 
spermatogenic cell apoptosis induced by estrogenic compounds (Alam et al., 2010).          
 
1.3.2(d)   Steroidogenesis 
 Steroidogenesis is defined as the biosynthesis of steroid hormones. Steroids 
synthesized in the sex organs, such as testes and ovaries are more commonly known as sex 
hormones. Cholesterol is the primary precursor of steroid hormone and the compound is 
synthesized from the precursor acetyl coenzyme A in the body (Solomons, 1996). In the 
Leydig cells, testosterone steroidogenesis can be virtually divided into two distinct upstream 
and downstream pathways. The upstream steroidogenesis pathway involves the initial 
binding of the agonist luteinizing hormone (LH), generation of cyclic adenosine 
monophosphate (cAMP), phosphorylation of protein kinase A (PKA) and transportation of 
cholesterol into inner mitochondria. In the downstream steroidogenesis pathway, cholesterol 
undergoes series of decarboxylation, oxidation and reduction processes involving a number 
of membrane bound cytochromic enzymes to produce testosterone (Fig. 1.3). Subsequently, 
the testosterone is transported into the Sertoli cell to the germ cells known as spermatocytes 
to facilitate the spermatogenesis process and also be further converted to estrogen by 
aromatase enzyme (CYP19) in seminiferous tubules.  
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Figure 1.3 Steroidogenesis pathways in the Leydig cells 
 
Luteinizing hormone (LH) is a type of gonadotropin, secreted from pituitary gland 
into blood stream, stimulated the Leydig cell to synthesize testosterone (Fig. 1.3). LH and 
human chorionic gonadotropin (hCG), a luteinizing-like hormone bind to the specific G 
Protein-coupled Receptor (GPCR), a seven-membered transmembrane receptor, activate the 
enzyme adenylyl cyclase to form secondary messenger cyclic adenosine monophosphate 
(cyclic AMP) (Browne and Bhalla, 1991). The cyclic AMP phosphorylates the protein 
kinase A (PKA) into the active form and the activated PKA in turn activates the steroidal 
acute regulatory protein (StAR) to deliver the cholesterol from cytoplasm (outer 
mitochondria) into the inner mitochondria (Stocco, 2000). In fact, the expression of the StAR 
genes was augmented with the elevated hCG level influenced by presence of calcium ion 
(Manna et al., 1999). Generally, cyclic AMP plays major role in the steroidogenesis and its 
concentration in the cell is maintained between the synthesis by adenylyl cyclase and the 
degradation by phosphodiesterases (PDEs) (Tsai and Beavo, 2011). Recent studies showed 
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that PDE4 and PDE8A modulated testosterone production in the mouse Leydig cells (Vasta 
et al., 2006; Tsai and Beavo, 2011). The inhibition of 3-isobutyl-1-methylxanthine (IBMX) 
on PDEs potentially elevates the cyclic AMP production (Vasta et al., 2006).         
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Steroidogenesis of testosterone from cholesterol. 
 
In the downstream steroidogenesis, cholesterol is converted to pregnenolone through 
the series of complicated enzymatic decarboxylation and reduction process catalyzed by the 
cytochrome P450SCC (CYP11a), side chain cleavage enzyme in the inner mitochondria. The 
pregnenolone is then translocated to the smooth endoplasmic reticulum (SER) where 
testosterone is synthesized from either dehydroepiandrosterone (∆5) pathway or progesterone 
(∆4) pathway (Fig. 1.4). The conversion of pregnenolone to the testosterone involves a series 
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of cytochrome P450 enzymes such as 17α-hydroxylase (CYP17), 17,20-lyase (CYP17), 17β-
hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase and ∆5,4-isomerase.  
 
The inhibitory effects of the above enzymes have significantly led to the 
development of drugs in the steroidogenesis modulation. Aminoglutethimide (AGTM), a 
potent CYP11a and CYP19 inhibitor was initially developed as the first generation non-
steroidal aromatase inhibitor but was not popularized due to the side effects (Chumsri et al., 
2011). The rate limiting step in the production of androgenic steroids is CYP17, located in 
testicular Leydig cells, that catalyzed the 17α-hydroxylase reaction and the subsequent 
17,20-lyase reaction to form the precursor for the steroidal hormone (Reid et al., 2008). 
Ketoconazole (KTZ), an imidazole antifungal agent, inhibited several cytochrome P450 
enzymes, including CYP17, decreased levels of testosterone, androstenedione and DHEA 
(De Coster et al., 2008). However, the use of KTZ as a secondary hormonal therapy for 
prostate cancer was limited by its toxicity (Reid et al., 2008).                      
 
1.3.2(e) Cross-talk between testosterone, estrogen hormones and cyclic AMP  
It is beyond doubt that testosterone is required for spermatogenesis. The production 
of testosterone is exerted by the cyclic AMP secondary messenger signaling pathway and 
influenced by the gonadotropins (Browne and Bhalla, 1991). Testosterone, the principal 
androgen and its metabolite mediate their effect mainly on the meiosis and spermiogenesis 
through the classical action by modulating the gene expression via the intracellular steroid 
binding androgen receptors and the non-classical actions that exert the rapid testosterone 
actions via membrane-associated androgen receptor (Rahman and Christian, 2007). The 
mitogenic effect of the androgen in the Sertoli cells was evidently proven following the 
activation of the two transcriptional factors, mitogen-activated protein kinase (MAPK) and 
cyclic AMP responsive element binding (CREB) protein by the testosterone (Fix et al., 2004). 
In order to ensure a stable germ cell population determined by the balance between the death 
(apoptotic) and proliferation of the cells (Ruwanpura et al., 2010), testosterone also acts co-
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operatively with follicle stimulating hormone (FSH) as a survival factor of germ cells by 
regulating both the intrinsic and extrinsic apoptosis pathways (Meachem et al., 2005).  
 
Beside the testosterone, estrogen, a steroid hormone also plays a role as the survival 
of the mammalian germ cells (Carreau et al., 2011). In the mammalian testes, estrogen was 
converted from the testosterone by the cytochrome P450 aromatase enzyme (CYP19) in the 
endoplasmic reticulum of the germ cells and the Leydig cells (Carreau et al., 2011). Thus, 
the inhibition on the CYP19 resulting in the reduction of the estrogen production has led to 
the development of the estrogenic-induced breast cancer chemotherapy drugs such as 
anastrozole (Arimidex®), exemestane (Aromasin®) and formestane (Lentaron®). Similar to 
the testosterone, estrogen acts via cyclic AMP signaling pathway with adenylyl cyclase 
stimulation effect (Aronica et al., 1994). However, estrogen showed the pro-apoptotic effect 
in addition to the anti-apoptosis effects on the different cell types. These divergent effects 
may probably correspond to the deviating effects possessed by the cyclic AMP where the 
molecule induced the apoptotic cell death in estrogen-responding MCF-7 breast cancer cell 
lines (Bøe et al., 1995) and human B-precursor cells (Myklebust et al., 1999) but prevented 
the CD34+ cell from apoptosis (Negrotto et al., 2006).  
 
Apparently, testosterone and estrogen are involved in the cell proliferation in 
spermatogenesis. Both steroidal hormones act towards the cyclic AMP secondary messenger 
signaling pathway to exert their biochemical effects. Testosterone binds to the androgen 
receptor to activate its biological effects and so does the estrogen. The effects of estrogen are 
mediated by two distinct receptors: estrogen receptor α (ERα) and estrogen receptor β (ERβ). 
Leydig cells express both ERα and ERβ (Akingbemi et al., 2003). The inactivation of ERα 
increased the gonadotropins and the testosterone (Akingbemi et al., 2003). Besides, the 
number of the Leydig cells was increased from the ERβ knockout mice (Gould et al., 2007). 
Thus, ERα may possess regulatory role in the steroidogenesis and ERβ may involve in the 
regulation of the Leydig cells proliferation.            
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